



Bioviser Universal Research has considerable experience of working with biomedical researchers and clinicians in furthering human health. Our expertise lies at the intersection of medical research, data science, and scientific communications. There is tremendous untapped potential for leveraging our services to drive efficiency and foster innovation in your pursuit for advancing human health research for space exploration.

We aim to translate our deep expertise in patient healthcare and clinical research to support researchers in their quest to develop countermeasures against spaceflight risks. Our technology-enabled solutions can be used in real-time health monitoring and other public health applications.

We will leverage our decadal experience in the pharmaceutical industry to contribute meaningfully to space health research. We envision a complementary role alongside industry peers, contributing to the growth and diversity of the space health research ecosystem.




# **BACKGROUND**

Supporting the development of efficient countermeasures against spaceflight-related risks, NASA's Human Research Roadmap is a compendium of interlinked Risks, Gaps, and Tasks, along with the associated publications. We believe that a **quantitative analysis of these publications may reveal new actionable insight on the research activities** supported by NASA's Human Research Program.

**Directed Acyclic Graphs (DAGs),** maintained by the Human System Risk Board (HSRB), are causal diagrams that demonstrate relationships between human system risks (**Figure 1**).<sup>2</sup> DAGs are intended to improve insight and communication of risks across the myriad of subject matter experts interested in human system risk reduction.

We tested an unconventional approach of mapping journal publications indexed in NASA's Task Book to risk concepts described in the DAGs in an attempt to reveal gaps and opportunities for further research into reducing human system risks.

Figure 1: DAG framework



# **METHODS**

Our analysis focused only on peer-reviewed journal articles published during 2018-2023 and indexed under "Human Research" in the NASA Task Book.3 Bibliographies were downloaded in Excel format by calendar year and references were deduplicated.

Based on the **research and keywords** described in the abstracts, each article was (1) **assigned to** one or more of the 30 **spaceflight Risks** and (2) **tagged with** several "**research concepts**" that we **coined from the Nodes terminology** used in DAGs.

We assessed the overall annual publication volumes and the number of journal articles for each Risk. We then tried to recognize trends in research based on the frequency of the research concepts.



Table 1. Volume of Human Research Literature Curated in the NASA Task Book bibliography\*

| Type of publication        | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|----------------------------|------|------|------|------|------|------|
| Abstracts                  | 186  | 148  | 135  | 164  | 191  | 102  |
| Peer-reviewed articles     | 283  | 249  | 330  | 289  | 234  | 146  |
| Deduplicated articles      | 194  | 171  | 220  | 188  | 180  | 107  |
| Other articles             | 4    | 8    | 13   | 6    | 1    | 3    |
| Papers from meetings       | 16   | 16   | 11   | 15   | 16   | 8    |
| Book chapters              | 5    | 11   | 42   | 5    | 6    | 4    |
| Dissertations and thesis   | 4    | 3    | 8    | 5    | 3    | 1    |
| NASA tech documents        | 5    | 1    | 0    | 6    | 0    | 0    |
| Patents                    | 0    | 1    | 0    | 0    | 1    | 0    |
| *Data cut-off Dec 31, 2023 |      |      |      |      |      |      |

Annual publication volumes appear stable and range bound for the assessment period **(Table 1)**. The spike in journal articles in 2020 during the pandemic may reflect greater researcher timeshare being devoted to paper writing than to activities requiring in-person collaboration.

A possible decline in journal articles in 2023 may be attributed to lag times in the publishing process or in recording the publications in the Task Book.

Approximately 30% of peer-reviewed journal articles were tagged to multiple HRR Tasks, reflecting the integrated systems approach to developing countermeasures.

**Table 2** shows the volume of journal articles bucketed by year and tagged to human system spaceflight risks as well as HSRB's assessment status for these risks as of June 2023.

By considering the **number of journal articles as a surrogate measure of research activity,** these data could help identify

- · Areas where additional research is required for risks to reach an acceptable level or
- Extensively researched areas where higher publication numbers would be expected.

For example, Sleep, Immune, and Microhost risks have a **similar HSRB assessment status**, while Sleep research has produced a **notably higher number of publications** than Immune or Microhost research.



Table 2. Volume of Peer-Reviewed Journal Articles from the NASA Task Book Plotted Against Human System Risks Based on Details in Abstracts

| the NASA Task       | able 2. Volume of Peer-Reviewed Journal Articles from<br>the NASA Task Book Plotted Against Human System Risks<br>ased on Details in Abstracts |           |          |        |      |      |       | NASA HSRB Risk Report Roll<br>up (June 2023)<br>In-mission Risk - Operations |                |                   |                    |                 |                    |           |                 |
|---------------------|--|-----------|----------|--------|------|------|-------|--|----------------|-------------------|--------------------|-----------------|--------------------|-----------|-----------------|
|                     |  | <b></b>   |          |        |      |      |       | 30 D   | LEO 30 D - 1 Y | Lunar Orbit <30 D | Lunar Orbit 30 D - | Lunar O+S <30 D | Lunar O+S 30 D - 1 | 17        | Mars 720 1224 D |
| Risks               | 2018   | 2019      | 2020     | 2021   | 2022 | 2023 | Total | LEO < 30 D   | 90             | mar (             | mar                | ınar            | mar (              | Mars <1 Y |                 |
|                     | Isol   | ation ar  | nd Confi | nement |      |      |       | - 5  | 5              | ت                 | ت                  | ت               | ت                  | Σ         | 2               |
| Behavioral Med      | 26   | 24        | 29       | 42     | 30   | 19   | 170   |  |                |                   |                    |                 | _                  |           |                 |
| Team                | 19   | 14        | 11       | 9      | 10   | 5    | 68    |  |                |                   |                    |                 |                    |           |                 |
|                     |  | Ra        | diation  |        |      |      |       |  |                |                   |                    |                 |                    |           |                 |
| Carcinogenesis      | 23   | 21        | 27       | 15     | 20   | 9    | 115   |  |                |                   |                    |                 | _                  |           |                 |
| Non-ionizing rad.   | 0  | 0         | 0        | 0      | 0    | 0    | 0     |  |                |                   |                    |                 |                    |           |                 |
|                     |  | Altere    | ed Gravi | ty     |      |      |       |  |                |                   |                    |                 |                    |           |                 |
| SANS                | 10   | 9         | 10       | 19     | 16   | 6    | 70    |  |                |                   |                    |                 |                    |           |                 |
| Cardiovascular      | 16   | 10        | 18       | 10     | 15   | 7    | 76    |  |                |                   |                    |                 |                    |           |                 |
| Muscle/Aerobic      | 6/3  | 12/2      | 6/0      | 3/0    | 3/0  | 3/0  | 33/5  |  |                |                   |                    |                 |                    |           |                 |
| Bone fracture       | 14   | 6         | 13       | 6      | 4    | 2    | 45    |  |                |                   |                    |                 |                    |           |                 |
| Renal stone         | 6  | 2         | 7        | 0      | 4    | 0    | 19    |  |                |                   |                    |                 | П                  |           |                 |
| Sensorimotor        | 22   | 5         | 9        | 10     | 11   | 6    | 63    |  |                |                   |                    |                 |                    |           |                 |
| Crew egress         | 0  | 1         | 1        | 0      | 5    | 0    | 7     |  |                |                   |                    |                 | П                  |           |                 |
| Urinary retn.       | 0  | 0         | 0        | 0      | 0    | 0    | 0     |  |                |                   |                    |                 |                    |           |                 |
| VTE concern         | 0  | 0         | 0        | 0      | 2    | 0    | 2     |  |                |                   |                    |                 |                    |           |                 |
|                     | Host   | tile Clos | ed Envi  | ronmen | t    |      |       |  |                |                   |                    |                 |                    |           |                 |
| Sleep loss          | 15   | 17        | 17       | 16     | 12   | 9    | 86    |  |                |                   |                    |                 |                    |           |                 |
| Immune              | 10   | 8         | 10       | 6      | 8    | 2    | 44    |  |                |                   |                    |                 |                    |           |                 |
| Microhost           | 5  | 4         | 6        | 9      | 6    | 3    | 33    |  |                |                   |                    |                 |                    |           |                 |
| Hearing loss        | 0  | 0         | 0        | 0      | 0    | 0    | 0     |  |                |                   |                    |                 |                    |           |                 |
| CO2                 | 0  | 3         | 1        | 0      | 0    | 0    | 4     |  |                |                   |                    |                 |                    |           | _               |
| Dynamic loads       | 0  | 3         | 1        | 2      | 0    | 0    | 6     |  |                |                   |                    |                 |                    |           | Г               |
| EVA                 | 0  | 0         | 0        | 1      | 0    | 0    | 1     |  |                |                   |                    |                 |                    |           |                 |
| Electrical shock    | 0  | 0         | 0        | 0      | 0    | 0    | 0     |  |                |                   |                    |                 |                    |           |                 |
| Toxic exposure      | 0  | 0         | 0        | 0      | 0    | 0    | 0     |  |                |                   |                    |                 | $\neg$             |           | _               |
| DCS                 | 0  | 0         | 0        | 0      | 0    | 0    | 0     |  |                |                   |                    |                 |                    |           |                 |
| Celestial dust      | 0  | 1         | 0        | 0      | 1    | 0    | 2     |  |                |                   |                    |                 |                    |           | Ē               |
| Hypoxia             | 0  | 0         | 0        | 0      | 0    | 0    | 0     |  |                |                   |                    |                 |                    |           |                 |
| Distance from Earth |  |           |          |        |      |      |       |  |                |                   |                    |                 |                    |           |                 |
| Medical cond.       | 1  | 9         | 10       | 11     | 13   | 15   | 59    |  |                |                   |                    |                 |                    |           |                 |
| Food & Nutrition    | 3  | 1         | 14       | 4      | 10   | 3    | 35    |  |                |                   |                    |                 |                    |           | Ē               |
| HSIA                | 3  | 1         | 0        | 4      | 3    | 5    | 16    |  |                |                   |                    |                 |                    |           |                 |
| Pharm               | 1  | 0         | 0        | 1      | 0    | 0    | 2     |  |                |                   |                    |                 |                    |           | Ē               |
|                     |  |           | le Haza  |        |      |      |       |  |                |                   |                    |                 |                    |           |                 |
| Multiple Risks      | 11   | 18        | 25       | 19     | 17   | 13   | 103   |  |                |                   |                    |                 |                    |           |                 |
| . luttipte maka     |  | 10        | 20       | 10     | 17   | 10   | 100   |  |                |                   |                    |                 |                    |           |                 |



Figure 2: Heatmaps of Research Concepts in Journal Articles Plotted Against Spaceflight Risks

|                 |   |      |         |          |        |           |           |         |      | Carcinogenesis |     | Muscle/Aerobic |      | ne          |      | otor           |
|-----------------|---|------|---------|----------|--------|-----------|-----------|---------|------|----------------|-----|----------------|------|-------------|------|----------------|
|                 | Research<br>Topics/Keywords in          | BMed | Team    | Sleep    | Immune | MicroHost | Nutrition | Medical | ⋖    | rcinog         | s   | scle/A         | e    | Renal stone | SANS | 2 Sensorimotor |
|                 | Journal Articles                        | Ξ    | Lea     | Se       | Ξ      | Ξ̈        | ž         | Ψ       | HSIA | Ca             | CVS | Ξ              | Bone | æ           | SAI  | Sel            |
|                 | Artificial gravity                      | 1    |         |          |        |           |           |         |      |                | 2   |                | 1    |             | 1    | 7              |
|                 | Cardiac changes                         | 1    |         | 4        | 1      |           |           | 1       |      |                | 38  | 1              |      |             |      |                |
| Ę.              | Muscle changes                          |      |         |          |        |           |           |         |      |                |     | 23             | 7    |             |      |                |
| rav             | Bone changes                            |      |         | 1        |        |           | 1         |         |      |                |     | 2              | 25   | 3           |      |                |
| Attered gravity | Nephrolithiasis                         |      |         |          |        |           |           | 1       |      |                |     |                |      | 10          |      |                |
| ere             | Ocular changes                          | 1    |         |          |        |           | 1         | 8       |      |                |     |                |      |             | 51   | 2              |
| Att             | ICP                                     | 3    |         |          |        |           |           |         |      |                | 1   |                |      |             | 14   | 2              |
|                 | Ruid shifts                             | 4    |         |          |        |           |           |         |      |                | 6   |                |      |             | 20   | 2              |
|                 | Sensorimotor-related                    | 4    |         |          |        |           |           |         |      |                |     | 1              |      |             | 1    | 24             |
|                 |   |      |         |          |        |           |           |         |      |                |     |                |      |             |      |                |
| Ē               | Cancer                                  |      |         | -        | 3      |           | -         | 1       |      | 36             | 1   |                | _    | 1           |      |                |
| Radiation       | Charged particles                       |      |         | 5        | 8      |           | 2         | 2       |      | 49             | 14  | 1              | 5    |             | 2    | 4              |
| 3g              | Radiation dose                          | 8    |         | 1        | 3      |           |           | 1       |      | 17             | 2   |                |      |             | 1    |                |
| æ               | Bystander effect                        | 3    |         |          |        |           |           |         |      | 8              | 3   |                |      |             |      |                |
|                 | DNA damage/repair                       | 2    |         |          | 1      |           | 1         | 1       |      | 29             | 1   |                |      |             |      |                |
|                 | Immune dysregulation                    | 8    |         |          | 15     | 5         | 2         | 2       |      | 8              | 3   | 1              |      |             |      |                |
| Closed hostile  | Infection                               |      |         |          | 5      | 10        |           | 7       |      |                |     |                |      |             |      |                |
| hos             | Microbiome                              | 5    |         |          | 1      | 24        | 9         | 2       |      |                |     |                | 1    |             |      |                |
| eq              | CO <sub>2</sub>                         | 4    |         |          |        |           | 5         |         |      |                |     |                |      |             | 5    | 5              |
| los             | Injury                                  | 3    |         |          | 1      |           |           |         |      |                |     | 1              | 1    |             |      |                |
| 0               | Sleep/Circadian                         | 4    | 1       | 53       |        |           |           |         |      |                |     |                |      |             |      |                |
|                 | DUD 44                                  | 40   | 4.0     | 10       |        |           |           |         |      | 4              |     |                |      |             |      |                |
| pa              | BHP factors<br>Cognitive function       |      | 16<br>6 | 12<br>13 | 1      |           | 1         | 1       |      | 1              | 1   |                |      |             |      | 6              |
| solatedconfined |   | 13   | 5       | 2        | 1      |           |           | 1       |      | 2              | 1   |                |      |             |      | О              |
| 50              | Psychologic factors<br>Scheduling/Shift | 13   | 3       | 11       |        |           |           |         | 2    |                |     |                |      |             |      |                |
| eq              | Workload                                | 3    | 1       | 1        |        |           |           |         | 2    |                |     | 1              |      |             |      |                |
| Sat             | Team dynamics                           | 4    | 51      | 1        |        |           |           |         | 2    |                |     | 1              |      |             |      |                |
| <u>8</u>        | Performance                             |      | 21      | 13       |        |           | 1         |         | 2    |                | 2   | 1              |      |             | 2    | 11             |
|                 | renonnance                              | 29   | 21      | 10       |        |           | 1         |         |      |                | 2   | 1              |      |             |      | 11             |
|                 | Aging                                   | 2    |         |          | 4      |           |           | 1       |      | 2              | 1   |                | 2    |             |      | 3              |
|                 | CNS changes                             | 67   |         | 5        | 3      | 2         |           | 3       | 1    |                | 2   |                |      |             | 12   | 14             |
|                 | Countermeasures                         | 17   | 2       | 9        | 4      | 2         | 4         | 2       |      | 7              | 9   | 4              | 3    | 2           | 13   | 6              |
|                 | Biomarkers                              | 5    |         | 6        | 8      | 4         | 4         | 8       |      | 6              | 6   | 1              | 1    | 2           | 4    | О              |
|                 | Diagnostics/Monitoring                  | 9    | 1       | 0        | 3      | 1         | 1         | 24      |      | 1              | 4   | 1              | 1    | 3           | 4    |                |
|                 | Individual factors                      | 1    | 1       | 8        | 3      | 1         | 2         | 1       |      | 1              | 3   | 1              | 1    | 3           | 1    | 1              |
|                 | Genomics                                | 1    | 1       | 2        |        | 13        | 2         | 3       |      | 15             | 3   | 1              | 2    |             | 1    | 1              |
|                 | Genomics                                | 1    |         | 2        |        | 13        |           | 3       |      | 10             | 3   | 1              |      |             | 1    |                |
| Common factors  | Nutrition & Food                        | 1    |         | 4        | 4      |           | 26        |         |      |                | 3   | 2              | 2    |             | 2    |                |
| act             | Metabolism                              |      |         | 5        |        | 1         | 1         | 1       |      |                | 1   |                |      |             |      |                |
| on              | Endocrine                               | 1    |         | 2        |        |           |           | 1       |      |                |     |                | 2    |             |      |                |
| Ě               | Exercise                                | 2    | 2       | 1        | 8      | 1         |           |         |      |                | 3   | 8              | 3    |             | 1    |                |
| 5               | Spaceflight stress                      | 15   |         | 1        | 8      | 2         |           |         | 1    |                | 3   |                | 1    |             |      | 1              |
| ٥               | Cell signaling                          |      |         |          | 2      |           | 1         |         |      | 7              | 2   |                | 2    |             | 1    |                |
|                 | Inflammation                            |      |         |          | 3      |           | 1         | 2       |      | 3              | 2   |                | 2    |             |      |                |
|                 | Oxidative stress                        | 6    |         | 1        |        | 1         | 3         |         |      | 6              | 5   | 2              | 2    |             | 2    |                |
|                 | Autono mou s system                     | 1    | 6       | 1        |        |           | 1         | 6       | 2    | 1              |     |                |      |             |      |                |
|                 | Medications/Drugs                       | 10   | U       | 1        | 4      | 1         | 2         | 7       | 2    | 11             | 3   | 2              | 2    |             |      |                |
|                 | Treatment/Therapy                       | 3    |         | 3        | 1      | 1         | _         | 10      |      | 2              | 2   | 2              | 1    | 6           |      | 1              |
|                 | Training                                | 3    | 5       | 1        | -      | -         |           | 5       |      | -              | 1   | -              | -    |             |      | 5              |
|                 | HSI                                     | Ü    |         | -        |        |           |           | ·       | 10   |                |     |                |      |             |      | Ü              |
|                 | 1131                                    |      |         |          |        |           |           |         | 10   |                |     |                |      |             |      |                |

Figures 2 shows a heatmap of research concepts from journal articles published during 2019-2023 **plotted** against spaceflight risks associated with the most publication activity. Such graphical analysis could reveal research gaps or help identify new opportunities. For example, bystander (non-targeted) effects of radiation have been studied mainly in cancer-related research and to a lesser extent in cardiovascular and BMed research. Thus, bystander effects may be studied in relation to other risk systems. Similarly, there may be opportunities to leverage the extensive research in biomarkers. genomics, diagnostics, and individual factors to develop personalized medicine approaches for astronauts.



# **Suppl. Table 1. Top Task Titles and Journals based on the highest number of journal articles published during 2018-2023**

| Task Title   | No. of articles |
|--|-----------------|
| Biomarkers as Predictors of Resiliency and Susceptibility to Stress in Space Flight  | 37              |
| An Integrated Framework for Characterization of the Noncoding Genome and Epigenome in Astronauts   | 33              |
| The Landscape of DNA and RNA Methylation Before, During, and After Human Space Travel  | 33              |
| NSCOR: Mechanisms Underlying Charged Particle-Induced Disruption of CNS Function   | 25              |
| Spaceflight Effects on Neurocognitive Performance: Extent, Longevity, and Neural Bases   | 25              |
| Changes in the Neuroproteome Associated with HZE-Induced Impairment of Cognition   | 22              |
| Space Biochemistry Profile   | 22              |
| Center for Research on Cardiac, Vascular, and Acute Effects of Space Radiation   | 21              |
| NSCOR: Space Radiation and Gastrointestinal Cancer: A Comprehensive Strategy for Risk Assessment and Model Development                         | 21              |
| NSCOR: NASA Specialized Center of Research on Carcinogenesis   | 19              |
| A Non-intrusive Ocular Monitoring Framework to Model Ocular Structure and Functional Changes due to Long-term Spaceflight                      | 18              |
| Fluid Distribution before, during and after Prolonged Space Flight   | 17              |
| Blood-based Multi-scale Model for Cancer Risk from GCR in Genetically Diverse Populations  | 17              |
| HZE Particle Exposure-Induced Improvement of Pattern Separation in Mature Mice: Alterations in Mission-Relevant Behaviors and Neural Circuitry | 16              |
| Effects of Long-Term Exposure to Microgravity on Salivary Markers of Innate Immunity   | 15              |
| Mechanistic Analysis of Particle Radiation-Induced Carcinogenesis Using Validated Mouse Glioma<br>Models                                       | 15              |

| Journal name                                | No. of articles |
|---|-----------------|
| Life Sciences in Space Research             | 55              |
| Scientific Reports                          | 49              |
| Radiation Research                          | 46              |
| Frontiers in Physiology                     | 31              |
| Aerospace Medicine and Human Performance    | 25              |
| Journal of Applied Physiology               | 25              |
| International Journal of Molecular Sciences | 21              |
| Acta Astronautica                           | 19              |
| Human Factors                               | 18              |
| npj Microgravity                            | 17              |
| Sleep                                       | 16              |

For the analysis period of 2018-2023, research on biomarker, genomics, and neurocognition produced the highest number of journal publications, followed by carcinogenesis, cardiovascular, and ocular. Life Sciences in Space Research, Scientific Reports, and Radiation Research were the top 3 journals.



# **Heatmap of Research Topics Covered in Literature Related to**

### **BMed Risk**

### Research Topics or Keywords in Literature Related to 2019 2020 2021 2022 2023 **BMed Risk** BHP factors 11 Bystander effect Charged particles CNS changes CO2 Cognitive function Countermeasures DNA damage/repair Exercise -1 Fatigue n n Fluid shifts n HLU/HDBR HSI ICP n n Immune Inflammation Medications/Drugs Microbiome Nutrition/food Oxidative stress Performance Psychologic Radiation dose Sensorimotor-related 1 Sensory augmentation Sleep n Stress Treatment Training - 1 Workload BHP assessed in literature related to other Risks Sleep Risk 2 3 Team Risk 5 1

### **Sensorimotor Risk**

| Research Topics or Keywords<br>in Literature Related to<br>Sensorimotor Risk | 2019 | 2020 | 2021 | 2022 | 2023 |
|--|------|------|------|------|------|
|  |      | 4    | 0    | 0    | 1    |
| Aging  | 1    | 1    |      |      |      |
| Adaptation   | 0    | 0    | 2    | 4    | 2    |
| Artificial gravity   | 0    | 0    | 2    | 1    | 4    |
| Charged particles  | 0    | 1    | 2    | 1    | 0    |
| CNS/Brain  | 0    | 4    | 5    | 3    | 2    |
| CO2  | 0    | 1    | 4    | 0    | 0    |
| Cognition  | 1    | 0    | 3    | 2    | 0    |
| Countermeasures  | 0    | 0    | 1    | 2    | 3    |
| Fine motor control   | 0    | 0    | 3    | 1    | 1    |
| HDBR   | 0    | 1    | 4    | 0    | 0    |
| Intracranial pressure  | 0    | 2    | 0    | 0    | 0    |
| Microgravity   | 1    | 1    | 1    | 1    | 2    |
| Multisensory integration   | 2    | 1    | 2    | 1    | 0    |
| Motion sickness  | 0    | 0    | 0    | 1    | 1    |
| Neuromo dulation   | 1    | 3    | 0    | 0    | 0    |
| Ocular   | 0    | 0    | 2    | 0    | 0    |
| Performance  | 1    | 2    | 3    | 3    | 2    |
| Postural control/locomotion  | 4    | 3    | 7    | 8    | 2    |
| Proprio ception  | 1    | 0    | 1    | 0    | 0    |
| Spatial orientation  | 2    | 1    | 3    | 3    | 2    |
| Training   | 1    | 1    | 0    | 2    | 1    |
| Vestibular factors   | 4    | 3    | 6    | 7    | 2    |
| Vestibuloocular  | 1    | 0    | 3    | 3    | 2    |
| Vision/gaze control  | 2    | 1    | 2    | 2    | 2    |
| and dealer outside   |      | -    |      |      |      |



### **BMed Risk**

| Research Topics or<br>Keywords in Literature<br>Related to Immune Risk | 2019     | 2020      | 2021    | 2022  | 2023 |
|--|----------|-----------|---------|-------|------|
| Aging  | 0        | 0         | 2       | 2     | 0    |
| Biomarker  | 2        | 3         | 2       | 1     | 0    |
| Cancer   | 1        | 0         | 1       | 1     | 0    |
| Cell signaling   | 1        | 1         | 0       | 0     | 0    |
| Charged particles  | 2        | 2         | 1       | 2     | 1    |
| CNS/Brain  | 1        | 1         | 0       | 1     | 0    |
| Cognition  | 0        | 0         | 0       | 1     | 0    |
| Countermeasures  | 2        | 1         | 1       | 0     | 0    |
| Diagnostics/Monitoring   | 1        | 0         | 1       | 1     | 0    |
| DNA damage/repair  | 1        | 0         | 0       | 0     | 0    |
| Exercise   | 1        | 4         | 3       | 0     | 0    |
| Hematopoietic  | 1        | 0         | 0       | 0     | 0    |
| Immune dysregulation   | 1        | 5         | 3       | 5     | 1    |
| Immune response  | 1        | 4         | 5       | 3     | 1    |
| Immunomodulation   | 2        | 3         | 0       | 2     | 0    |
| Infection  | 0        | 3         | 1       | 1     | 0    |
| Inflammation   | 2        | 1         | 0       | 0     | 0    |
| Injury   | 0        | 1         | 0       | 0     | 0    |
| Lab/Biochemistry   | 1        | 0         | 0       | 1     | 1    |
| Medical illness  | 1        | 0         | 0       | 2     | 0    |
| Medication/Drug  | 0        | 3         | 0       | 1     | 0    |
| Microbiome   | 0        | 0         | 0       | 1     | 0    |
| Microgravity   | 0        | 2         | 0       | 0     | 0    |
| Nutrition/Supplements  | 1        | 1         | 0       | 1     | 1    |
| Omics  | 2        | 2         | 2       | 1     | 2    |
| Radiation dose   | 1        | 0         | 1       | 1     | 0    |
| Spaceflight stress   | 3        | 2         | 0       | 2     | 1    |
| Treatment/Therapy  | 0        | 0         | 0       | 1     | 0    |
| Vaccination  | 2        | 0         | 2       | 0     | 0    |
| Viral reactivation   | 2        | 4         | 0       | 1     | 0    |
| Immunology in lite   | rature i | related t | o other | RISKS |      |
| BMed Risk  | 1        | 1         | 2       | 1     | 1    |
| Carcinogenesis Risk  | 1        | 4         | 4       | 0     | 0    |
| Cardiovascular Risk  | 1        | 1         | 0       | 1     | 1    |
| Microhost Risk   | 1        | 3         | 0       | 1     | 0    |
| Muscle Risk  | 0        | 1         | 0       | 0     | 0    |
| Medical Risk   | 0        | 1         | 6       | 0     | 0    |



# DISCUSSION

Through this unconventional approach, we aimed to introduce an alternative approach for researchers to analyze literature in their fields and draw conclusions based on their subject area expertise, rather than make concrete recommendations for further research.

**Research funding agencies and administrators** may adapt this approach to their planning and auditing activities.

The **subjectivity** in interpretation and tagging of journal articles to research concepts **is a limitation of our approach.** Also, the analysis focused solely on journal articles curated in the Task Book bibliography, which may not be fully representative of the ongoing research activity. A **more detailed qualitative gap analysis** of literature would yield more granular and precise insight on research needs.

Some of our **recommendations** from conducting this task are as follows:

- Given the ongoing development of the Mega DAG, our approach could be adapted to create a
  hyperlinked interactive tool, where individual publications are tagged to one or more relevant
  DAG nodes and are easily retrievable for an on-demand comprehensive assessment of the risk
  status.
- We noticed keywords closely corresponding to DAG terminology in a small proportion of publications. This practice should be encouraged to support the development of tools based on literature indexing.
- A bottom-up approach through literature analysis may yield new insight into DAG structure and nomenclature. For example, the concept of attention/alertness may need coverage in either BMed, Sensorimotor, or Sleep DAG.

# REFERENCES

- 1. Human Research RoadMap. https://humanresearchroadmap.nasa.gov/evidence/
- 2. Directed Acyclic Graph Guidance Documentation. https://ntrs.nasa.gov/citations/20220006812
- 3. NASA Task Book Bibliography. https://taskbook.nasaprs.com/tbp/index.cfm?action=bib\_search

